American Heart Association

clinical

ESO-WSO 2020: “Novel Imaging in Stroke”

Ammad Mahmood, MBChB
@AMahmoodNeuro

European Stroke Organisation-World Stroke Organization 2020 Virtual Conference
November 7-9, 2020

This session covered a number of novel techniques used in stroke imaging with a number of distinguished speakers. Cutting-edge advances in pre-hospital imaging in the ambulance, imaging used in making decisions about reperfusion therapies, and diagnostic imaging used in aetiological classification were all discussed.

Pre-hospital imaging – Jeffrey Saver
Advantages of triage in the field of patients into ischemic (LVO and non-LVO) and hemorrhagic stroke enables routing to the most appropriate facility, minimizing delays to treatment access and the need for inter-hospital transfers. Quasi-imaging approaches involving innovative approaches such as radio frequency, infrared, or EEG ‘stroke helmets’ may help identify patients with LVO in the future. Ultrasound assessment of vessel patency in the field yielded 91% accuracy in identifying LVO in one study. Mobile stroke units with CT capability are already in use and allow CT, CTA, and possibly CTP in the field. Automated image processing software can aid in interpretation of CT results quickly. Future technologies may include mobile stroke units in helicopters or small aircraft, mobile neuro-intervention suites, and mobile MRI imaging. Prof. Saver presented some cases from the Los Angeles mobile stroke unit experience highlighting the optimization of patient management achieved through early triage. Lastly, he highlighted the ongoing BEST-MSU trial, which will evaluate the benefit of MSUs in stroke management in several cities in the United States.

Automated image processing software – Bruce Campbell
The advantages of using processing software include speed, improved sensitivity, and standardization of analysis, particularly in settings where local expertise in image interpretation may not be available. Based on clinical trials which have utilized CT perfusion analysed volumes as inclusion criteria, software can help identify patients eligible for thrombolysis and thrombectomy, particularly late window patients. Treatment decisions in groups such as minor stroke or patients with co-morbidities who may not fit usual trial criteria can be made easier by looking for a perfusion mismatch. Prof. Campbell highlighted the capabilities of several packages, including automated ASPECTS assessment, hypodensity volume estimation, hyperdense artery identification, hemorrhage identification, LVO detection, collateral assessment, and ischemic core and penumbra prediction.

Carotid plaque imaging – Marie-Luise Mono
Asymptomatic moderate to severe carotid stenosis or symptomatic mild carotid stenosis are both challenging scenarios when determining stroke aetiology. Detailed imaging of plaques can reveal features of vulnerable plaques, such as intra-plaque hemorrhage, which contribute to the enlargement of the lipid-rich necrotic core and rapid plaque progression. Modalities used can include CT, MRI, and ultrasound; MRI and ultrasound provide the best imaging of plaque characteristics. Whilst most of these techniques remain research-based, T1 MRI imaging is widely available and could be used to identify high-risk plaque.

Comprehensive cardiac assessment by CT – Keith Muir
Secondary prevention beyond antiplatelets and statin depends upon the aetiological mechanism identified by investigations after stroke. The cause is cryptogenic in a significant proportion of cases. The standard of investigation which needs to be completed before declaring a case ‘cryptogenic’ is not universal, and access to modalities of investigation is variable worldwide. Delayed aetiological diagnosis leads to delayed management during the period of greatest risk for recurrent stroke. One option for rapid, universally available, combined assessment of cardioembolic and large vessel disease is contrast CT extended beyond the aortic arch to include cardiac imaging. Prof. Muir presented results of the D-CCIST pilot study from our center in Glasgow, which compared comprehensive cardiovascular imaging (CCI) which comprised of cardiac CT, CTA arch to vertex, and 3T MRI brain at a single visit against routine imaging for patients presenting within 7 days of TIA or acute stroke. A significantly higher proportion of patients with CCI had a definite aetiology identified by day 7 though not at day 30. Time to access investigations was not different between groups, but the time to identification of the aetiological cause was significantly shorter in the CCI group (51 hours) vs routine (82 hours). A larger trial of this approach to determine whether it can reduce recurrent clinical events is warranted.

When is arterial wall imaging useful? – Catherine Oppenheim
While imaging of the vessels with angiography is widely used and interpreted in acute stroke, vessel wall imaging remains a specialized assessment. Prof. Oppenheim highlighted 4 cases where MRI assessment of the vessel wall was used to make the diagnosis. The T1 MRI sequences used are possible on most scanner types. The cases included progressive carotid stenosis with intraplaque hemorrhage; transient perivascular inflammation of the carotid artery (TIPIC syndrome); dissection of the basilar artery; and VZV related cerebral vasculitis in a patient with HIV.

Imaging in wake-up stroke – Jochen Fiebach
Lastly, one of the authors of the WAKE-UP trial described the concept of DWI-FLAIR mismatch, which was developed from serial MRI imaging of patients with known times of symptom onset. In this cohort, it became clear that the majority of patients with DWI lesions did not develop FLAIR lesions until around 4.5 hours. This led to the WAKE-UP trial, which demonstrated a clear benefit in functional outcome for patients with DWI-FLAIR mismatch receiving thrombolysis versus placebo. A helpful online training tool from the WAKE-UP cohort has also been developed, allowing trainees to analyze a set of scans from the trial for DWI-FLAIR mismatch.

ESO-WSO 2020: “COVID-19 Related Stroke”

Ericka Samantha Teleg, MD

European Stroke Organisation-World Stroke Organization 2020 Virtual Conference
November 7-9, 2020

Navigating through this time of a pandemic is challenging enough as we attempt to seek and learn knowledge to compensate for how COVID-19 changes our lives. The special part of the scientific session “COVID-19 Related Stroke,” held during the ESOC-WSO 2020 conference on November 9, was structured brilliantly, led off by Dr. Bernard Yan’s opening.

The session by Karl Shurr and Annie McCluskey of Australia was titled “Rehabilitation for Serious COVID: Physiotherapist as Patient.” Karl’s experiences with COVID teaches us that one can be resilient at this time. He informed us how he used his time in the hospital to motivate himself and hopefully will motivate others, as well. Goal-setting as a motivation is the key in this session. We always ponder on what we cannot do, but his valuable insight as he recovered was “find what the person can do.” Empowerment and kindness are key.

ESO-WSO 2020: “Large Clinical Trials and Welcome”

Ammad Mahmood, MBChB
@AMahmoodNeuro

European Stroke Organisation-World Stroke Organization 2020 Virtual Conference
November 7-9, 2020

Welcome
Profs. Jesse Dawson and Michael Brainin welcomed all the delegates to the virtual conference and a chance to bring stroke care back into focus after a difficult year focusing on the COVID-19 pandemic. They spoke about the hard work that has gone into the rearrangement of this year’s conference into a virtual experience, and we thank them and their teams for their efforts in bringing the conference to us in these difficult times.

Fluoxetine after stroke
The first two presentations focused on the use of fluoxetine after stroke to assess any benefit in stroke rehabilitation and functional outcome. These trials came from an international collaboration of 3 trials focusing on this topic. First, Erik Lundstrom from Sweden presented the results of the EFFECTS trial. 1500 patients, at 35 Swedish centers, with ischemic or hemorrhagic stroke in the last 2-15 days but no history of depression were randomized 1:1 to receive either fluoxetine or placebo. The primary outcome of modified Rankin scale at 6 months demonstrated a neutral result with odds ratio 0.94 (0.78-1.13) at 6 months. Secondary outcomes demonstrated a small decrease in depression after stroke but a small increase in rates of fractures. Next, Graeme Hankey from Australia presented the 12-month results from the AFFINITY trial, which had also shown neutral results when the main trial results for 6 months outcome were previously published. The 12-month outcomes also showed a neutral effect of fluoxetine in functional outcome showing there is no delayed benefit. A small reduction in the rate of recurrent ischemic stroke in the fluoxetine group was seen in the AFFINITY trial, but not in the two other larger trials; therefore, this was felt to be a random effect. Overall, the results of the EFFECTS, AFFINITY, and FOCUS trials demonstrated that there is no benefit of fluoxetine after stroke in improving rehabilitation and functional outcome.

Ticagrelor in minor stroke and TIA
Next, Clay Johnston from Texas presented the results of the THALES trial. Dual antiplatelet therapy with aspirin and clopidogrel has become common practice after the POINT and CHANCE trials. The SOCRATES trial did not show any benefit on ticagrelor monotherapy versus aspirin monotherapy, and the THALES trial now examined dual antiplatelet therapy with ticagrelor and aspirin versus aspirin alone in minor stroke (NIHSS ≤5) and high-risk TIA (ABCD2≥6 or >50% symptomatic arterial stenosis) within 24 hours. 11016 patients were randomized 1:1 at 414 sites in 28 countries. Results showed a benefit of ticagrelor and aspirin over aspirin alone in the primary outcome of reduction in recurrent stroke or death at 30 days with a hazard ratio of 0.83 (0.71-0.96); most of the benefit was attributable to reduction in recurrent stroke in the first 7 days. However, there was a significant additional risk of hemorrhage in the ticagrelor group with a hazard ratio of 3.99 (1.74-9.14), though a small absolute difference. Overall, the authors helpfully summarized the effect as “for every 1000 patients treated, 11 strokes or deaths were prevented but 4 severe hemorrhages were produced.”

EVT in basilar artery occlusion
Wouter Schonewille from the Netherlands presented the results of the BASICS trial tackling one of the most difficult clinical problems in acute stroke, basilar artery occlusion. The trial randomized patients to either endovascular treatment plus best medical management (EVT + BMM) or best medical management (BMM) alone within 6 hours of the estimated time of basilar artery occlusion. They allowed inclusion of cases with stuttering onset as the time of basilar artery occlusion was taken as the point of acute severe deterioration. 300 patients were randomized in Europe and Brazil. The primary outcome of favorable functional outcome was neutral with 44.2% of EVT + BMM and 37.7% of BMM achieving mRS 0-3 with a risk ratio of 1.18 (0.92-1.50). There was no significant difference in rate of symptomatic ICH or mortality. The absolute risk reduction of 6.5% in the EVT group suggested a trend towards benefit of EVT. In subgroup analysis, patients presenting with NIHSS >10 showed a significant benefit of EVT. The authors concluded that EVT was safe within 6 hours and may be a better option for patients with NIHSS>10. The role of EVT beyond 6 hours and with minor deficit remains unclear.

LVO – where to?
Planning of stroke services worldwide involves deciding whether patients should be taken by the ambulance initially to the nearest stroke center or direct to a comprehensive stroke center where EVT is available. Next, Natalia Perez de la Ossa and Marc Ribo from Catalonia presented the results of the RACECAT trial. 1401 patients who resided in areas served by non-EVT stroke centers with suspected LVO according to the RACE score were randomized while in the ambulance to either proceed to the local stroke center (drip and ship) or direct to the EVT-capable center (mothership). The primary outcome of functional outcome measured by mRS in patients with ischemic stroke only was neutral. Mean time from symptom onset to arrival at the first center was 142 minutes in the drip-and-ship model and 216 minutes in the mothership model. Two-thirds of patients identified by the RACE score had ischemic stroke and two-thirds of these had LVO. Symptom onset to IV thrombolysis and EVT was 120 minutes and 270 minutes, respectively, in the drip and ship patients, and 155 minutes and 214 minutes, respectively, in the mothership patients. Overall, this well-designed trial answers an important question, and although planning of stroke services will always depend upon local needs, the validation of both drip-and-ship and mothership models is valuable.

Cryptogenic stroke – PFO closure vs antiplatelets
Next, Scott Kasner presented long-term outcomes from the REDUCE study of PFO closure vs antiplatelet therapy. Patients aged 18-59 with cryptogenic stroke and a PFO confirmed by echocardiography were randomized to either PFO closure plus antiplatelet therapy or antiplatelet therapy alone. In keeping with the previously published results in earlier follow up, the PFO closure group had a lower rate of recurrent ischemic stroke with a hazard ratio of 0.31 (0.13-0.76) though the absolute numbers of recurrent events are small especially in the latter years of the 5-year follow-up period. Significantly, more patients in the PFO group developed atrial fibrillation in the follow-up period. Most AF was peri-procedure though 2.7% of the PFO group (vs 0.4% in antiplatelet only) developed persistent or permanent AF and required anticoagulation. 

Closing
A Q&A panel was held to close out the session with speakers exploring some of the points of interest. Overall, despite the neutral results of many of the trials presented, important take-home messages about issues that the stroke community grapples with on a day-to-day basis — such as ‘mothership vs drip-and-ship’ care pathways, optimal management of basilar artery occlusion, and cryptogenic stroke — all contributed to an informative opening session at the conference. Of note, whilst this year’s conference aimed for greater gender balance and wider geographic representation, the large clinical trials sessions were noticeably lacking in this regard and demonstrate areas of improvement for the stroke community. More female representation and experiences of stroke care in the developing world shared on the largest stage at global conferences should continue to be in our collective aims for future conferences.

Dual Antiplatelet Therapy: Shotgun or Aiming at Precision Targets?

Thomas Raphael Meinel, MD
@TotoMynell

Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, Johnston SC, on behalf of the THALES Steering Committee and Investigators. Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke. 2020.

Short-term dual antiplatelet therapy (DAPT) has emerged as a powerful treatment option in patients with non-severe ischemic stroke or high-risk TIA.1 However, the efficacy of antithrombotic therapy might vary according to etiology of the ischemic event.2 Amarenco et al. aimed to investigate whether the efficacy and safety of DAPT with Aspirin plus Ticagrelor as compared to Aspirin differed in the subgroup of patients with minor stroke or TIA due to atherosclerotic vascular disease.

For this purpose, the authors conducted a substudy of the THALES trial including patients aged 40 years or older with non-severe non-cardioembolic ischemic stroke (NIHSS ≤5) or high-risk TIA (ABCD2-Score ≥6 or vascular stenosis ≥50% in the suspected vascular territory). Main exclusion criteria were atrial fibrillation, suspicion of cardioembolic cause, high bleeding risk and — importantly — planned carotid revascularization that required halting study medication within 3 days of randomization. or the main prespecified analysis, atherosclerotic ipsilateral stenosis was defined as presence of narrowing of the lumen of ≥30% ipsilateral to the ischemic event as assessed by CT- or MR-angiography or neurovascular ultrasound. The primary efficacy endpoint was time from randomization to the first subsequent event of stroke or death. The primary safety endpoint was occurrence of a severe bleeding event according to the GUSTO definition. 11,016 patients underwent randomization (roughly 50% representing a European and 40% Asian population).

ESO-WSO 2020: Stroke Imaging: Improved Decision-Making Through Machine Learning?

Tolga D. Dittrich, MD

European Stroke Organisation-World Stroke Organization 2020 Virtual Conference
November 7-9, 2020

Scientific Session: “Artificial Intelligence in Stroke Imaging,” Sunday, November 8, 2020
Speakers: Susanne Wegener, Roland Wiest, Paul Bentley, Kim Mouridsen, Sook-Lei Liew
Chairs: Kim Mouridsen, Susanne Wegener

Machine learning (ML) methods as a component of artificial intelligence are a growing field in stroke imaging research. We are already familiar with such automated evaluation systems, such as ASPECT scoring or mismatch volume calculation. Nevertheless, clinicians are often confronted with a complex mixture of different clinical, laboratory, and radiological parameters that must be weighed against each other to make an individual therapeutic decision.

“Machine learning is a precise mathematical way in which we can do this in a reliable, objective manner,” said Paul Bentley, of Imperial College London. Unlike conventional image interpretation, an algorithm can evaluate radiological source data to derive applicable rules. ML approaches are particularly promising for objectifying imaging results and detecting subtle changes in the context of intricate radiological findings in acute ischemic stroke. However, to provide additional information, ML methods need a relatively large set of initial data. This limitation especially becomes relevant in the context of imaging-based prediction of stroke recovery and rehabilitation response, where imaging does not constitute a common clinical component, as Sook-Lei Liew from the University of Southern California emphasized in her lecture.

The potential of ML in both acute stroke and stroke rehabilitation imaging is broad. In the future, ML-based techniques, for example, in ischemic core imaging in the extended time window, could help us to identify better patients who could benefit from endovascular treatment.

ESO-WSO 2020: “Young Stroke Physicians and Researchers: Research Design Workshops”

Tamaya Van Criekinge, PT
@tamayavc

European Stroke Organisation-World Stroke Organization 2020 Virtual Conference
November 7-9, 2020

Professor Karin Klijn from the Radboud University Medical Center started the session by providing young researchers with key steps when planning a career as a clinical scientist. With a little help from John F. Kennedy, she used a very relevant quote multiple times: “Those who dare to fail miserably can achieve greatly.” This advice continued throughout all the steps as she emphasized that it is important for you, as a young researcher, to take the initiative to further your own career. “Things do not happen, things are made to happen,” you, as a researcher, need to take the first step and take responsibility, while maintaining your own standards when finding a mentor, a supportive environment, and training.

The importance of a mentor was clarified by Prof. Peter Sandercock from the University of Edinburgh, who defined a mentor as an experienced, high-regarded empathic person who guides a young researcher throughout his or her career. When seeking a supervisor, you should look for someone who is already performing independent research but has a genuine interest in your academic career, who you can trust and have a good personal relationship with. Avoid bad mentors who exploit you, steal your ideas, or claim authorship for your work. Try and plan consecutive meetings with your mentor where you not only discuss work but how you tackle problems and how to overcome the pitfalls and downsides of an academic career. Yes, we have all received rejection letters! Yes, we have all had our own ups and downs! No, it’s nothing to be ashamed of.

ESO-WSO 2020: Three Rounds of Controversies in Stroke Thrombectomy

Aurora Semerano, MD
@semerano_aurora

European Stroke Organisation-World Stroke Organization 2020 Virtual Conference
November 7-9, 2020

The Controversy sessions in the ESO-WSO 2020 Conference are intriguing live Q&A sessions focused on grey zones in real-world stroke care, with stroke experts defending their points of view and facing each other in interesting rounds of discussion. On the first day of this ESO-WSO 2020 Conference, the session addressed the following hot topics about endovascular thrombectomy.

Do We Need Perfusion Imaging to Guide MT In Extended Time Window?

YES: Götz Thomalla (Germany) presented the pros of using advanced perfusion imaging for patient eligibility to mechanical thrombectomy (MT) in the extended time window (>6h from onset). He invited us to remember that, first of all, we should rely on current evidence. According to the evidence, whereas perfusion techniques are not required in the early time window, the DAWN and DEFUSE III clinical trials firmly base on advanced imaging for patient selection in the late time window. As a consequence, also AHA/ASA guidelines, ESO consensus, and ESMINT guidelines recommend advanced imaging for patient eligibility. He also pointed out that we cannot reliably trust the ASPECTS score for estimating viable tissue. In addition, against the opinion that perfusion techniques are time-consuming and difficult to interpret, Prof. Thomalla reassured that just a few minutes are needed to perform reliable perfusion imaging and that simple parameters are required for map interpretation: Tmax> 6 seconds identifies penumbra and CBF<30% works for infarct core. This little extra time is well invested to effectively guide reperfusion treatments.

Multimodal Stroke CT in the COVID-19 Era: More With Less

Elena Zapata-Arriaza, MD
@ElenaZaps

Esenwa C, Lee J-A, Nisar T, Shmukler A, Goldman I, Zampolin R, Hsu K, Labovitz D, Altschul D, Haramati LB. Utility of Apical Lung Assessment on Computed Tomography Angiography as a COVID-19 Screen in Acute Stroke. Stroke. 2020.

Acute ischemic stroke (AIS) management has changed since the beginning of the COVID-19 pandemic. Chart flows and assessment protocols have evolved with the aim of redirecting stroke and COVID-19 patients to places prepared for their management. The use of thorax CT has been implemented in patients with ischemic stroke, to identify patients infected with SARS-Cov-2, regardless of respiratory symptoms.

At the beginning of 2020, it was difficult for a vascular neurologist to imagine how essential it is to perform an accurate thoracic imaging test in those patients with ischemic stroke. Although these measures have improved patient management circuits, they have also led to an increase in the time to revascularization treatments with the impact that this entails. Taking advantage of the CT angiography protocols performed in stroke codes, evaluating the diagnostic accuracy of apical lung exam to identify patients with COVID-19, has been the authors’ aim.

Author Interview: Dr. Mitchell S. V. Elkind on “Approaches to Studying Determinants of Racial-Ethnic Disparities in Stroke and Its Sequelae”

Dr. Mitchell S. V. Elkind
Dr. Mitchell S. V. Elkind

Dr. Mitchell S. V. Elkind, MD, MS, FAAN, FAHA, is a Professor of Neurology and Epidemiology at Columbia University Irving Medical Center. He is the Head of the Division of Neurology Clinical Outcomes Research and Population Sciences (NeuroCORPS). Presently, he serves as the president of the American Heart Association.

He is interviewed by Dr. Melanie R. F. Greenway, MD, vascular neurology fellow at Mayo Clinic in Jacksonville, Florida.

They will be discussing the paper “Approaches to Studying Determinants of Racial-Ethnic Disparities in Stroke and Its Sequelae,” published in the November 2020 issue of Stroke. The article is part of a Focused Updates series of articles on topics related to health equity.

Dr. Greenway: To start, I would like to thank you for writing this comprehensive review on studying race-ethnic disparities in stroke as part of this unique series of articles in Stroke on health equity. This review provides an important framework for anyone embarking on their own epidemiologic research, as well as those of us reading and interpreting the race-ethnic disparities literature that is rapidly evolving. To start, you describe health disparities between groups as “a difference with a difference.” Can you explain what you mean by this?

Dr. Elkind: Disparities refer to differences in health that result from a very specific set of reasons, such as social, economic, or environmental disadvantage. There are many reasons why people may have different health outcomes, but when we talk about disparities, we are referring to differences that are often due to being part of a particular race or ethnic group, or to being part of another group that has historically experienced disadvantage.

By |November 5th, 2020|clinical|0 Comments

Article Commentary: “Inaugural Health Equity and Actionable Disparities in Stroke: Understanding and Problem-Solving Symposium”

Ericka Samantha Teleg, MD

Towfighi A, Benson RT, Tagge R, Moy CS, Wright CB, Ovbiagele B. Inaugural Health Equity and Actionable Disparities in Stroke: Understanding and Problem-Solving Symposium. Stroke. 2020;51:3382–3391.*

Health disparities in gender, class, race, and ethnicity exist. In the scientific community, this is a sad truth as well. Many of us researchers, physicians, and scientists are underrepresented. The Health Equity and Actionable Disparities in Stroke: Understanding and Problem-solving (HEADS-UP) symposium is meant to shatter these disparities, breaking through such barriers of social injustice, color, and caste systems. Researchers are key to resolve this challenge and advocate for the underrepresented minorities (URM) in the health system. This community will enable us to identify the differences in the biological, social, and environment that affect the continuum of care access and ensure quality care is given to underrepresented individuals.

The term URM stands for underrepresented minorities, and, as a consequence, clinicians and scientists will unite — hence, URM faculty will engage in research endeavors to reduce such differences among the underserved and/or low-income communities and make certain of the representation of the group in large clinical trials. There is strength in numbers, and clearly HEADS-UP is a voice for URM scientists.

By |November 4th, 2020|clinical|0 Comments